-
公开(公告)号：US20220168410A1
公开(公告)日：2022-06-02
申请号：US17672126
申请日：2022-02-15
Applicant: Pfizer Inc.
Inventor： Robert G.K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , C08B37/00 , A61P31/04 , A61P37/04
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
公开(公告)号：US20200123206A1
公开(公告)日：2020-04-23
申请号：US16713782
申请日：2019-12-13
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: C07K14/22 , A61K39/095
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
公开(公告)号：US20170182151A1
公开(公告)日：2017-06-29
申请号：US15385611
申请日：2016-12-20
Applicant: Pfizer Inc.
Inventor： Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , C07K14/005 , C12N7/00
CPC classification number: A61K39/155 , A61K39/12 , A61K2039/575 , C07K14/005 , C07K2319/02 , C07K2319/21 , C07K2319/22 , C07K2319/40 , C07K2319/70 , C07K2319/735 , C12N7/00 , C12N2760/18522 , C12N2760/18534 , C12N2760/18571
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
4.发明申请公开(公告)号：US20150291940A1
公开(公告)日：2015-10-15
申请号：US14436875
申请日：2013-10-07
Applicant: PFIZER INC.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
IPC: C12N9/10
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
Abstract translation: 一方面，本发明涉及包含突变型艰难梭菌毒素A和/或突变型艰难梭菌毒素B的免疫原性组合物。突变毒素可以包括具有至少一个突变的葡糖基转移酶结构域和至少具有至少一个突变的半胱氨酸蛋白酶结构域 一个突变，相对于相应的野生型艰难梭菌毒素。 突变毒素可以包括至少一个化学交联的氨基酸。 另一方面，本发明涉及用于培养艰难梭菌和产生艰难梭菌毒素的方法和组合物。
-
公开(公告)号：US11952597B2
公开(公告)日：2024-04-09
申请号：US16922952
申请日：2020-07-07
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
CPC classification number: C12N9/1051 , C07K14/33 , C12N1/20
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
Patent Agency Ranking
公开(公告)号：US20210024903A1
公开(公告)日：2021-01-28
申请号：US16922952
申请日：2020-07-07
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20200061177A1
公开(公告)日：2020-02-27
申请号：US16534457
申请日：2019-08-07
Applicant: Pfizer Inc.
Inventor： Robert G.K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , C08B37/00 , A61P37/04 , A61P31/04
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
公开(公告)号：US20190125861A1
公开(公告)日：2019-05-02
申请号：US16242799
申请日：2019-01-08
Applicant: Pfizer Inc.
Inventor： Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , C07K14/005 , A61K39/12 , C12N7/00
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
公开(公告)号：US10226525B2
公开(公告)日：2019-03-12
申请号：US15144884
申请日：2016-05-03
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G. K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US12128095B2
公开(公告)日：2024-10-29
申请号：US17672126
申请日：2022-02-15
Applicant: Pfizer Inc.
Inventor： Robert G. K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , A61K39/00 , A61P31/04 , A61P37/04 , C08B37/00
CPC classification number: A61K39/0258 , A61P31/04 , A61P37/04 , C08B37/006 , A61K2039/6037 , A61K2039/627
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.025 seconds)
